Avenio Tumor Tissue CGP Kits

The AVENIO Tumor Tissue CGP Kit is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. Designed to match the content of the 324 gene FoundationOne^® CDx panel, the kit leverages the proven technology of Foundation Medicine and Roche’s expertise to help your lab obtain reliable genomic insights.

Leveraging the FoundationOne® comprehensive genomic profiling (CGP) secondary analysis platform and the AVENIO workflow, our kit is part of Roche’s broad portfolio that offers flexible solutions and support services to meet your research needs. So you can get deeper genomic insights about solid tumors right in your lab — and advance discovery.

The power of precession medicine

CGP offers the greatest insights from a single assay leveraging NGS to broadly analyze regions of the tumor genome that other tests miss.

Avenio Tumor Tissue CGP Kit offers the greatest insights from a single assay leveraging NGS to broadly analyze regions of the tumor genome that other tests miss.

Features and Benefits of AVENIO Tumor Tissue CGP Kit

Designed to match the content of the 324 gene FoundationOne^® CDx panel, offering more insights and fewer missed opportunities than single biomarker or hot spot testing to help identify relevant alterations.
Detects all four mutation classes SNVs (single nucleotide variants), InDels (insertions or deletions), CNAs (copy number alterations) and Rearangements in a single DNA workflow¹
Identifies three genomic signatures: tumor mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH)¹
Utilizes a streamlined, end-to-end DNA-only hybrid capture workflow from extraction to secondary analysis results in 5 days
Provides an integrated solution that includes reagents and intuitive analysis and results generation to facilitate in-house adoption of a high performing NGS assay for oncology research.